These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31102935)

  • 1. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
    Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M
    Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
    Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
    J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
    Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
    Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
    Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
    Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.
    Reis-Mendes A; Carvalho F; Remião F; Sousa E; Bastos ML; Costa VM
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30862114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts.
    Jain A; Rani V
    Mol Cell Biochem; 2018 May; 442(1-2):81-96. PubMed ID: 28929270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li Y; Yu Q; Guo C; Li X
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):238-44. PubMed ID: 23770382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations.
    Henderson KA; Borders RB; Ross JB; Abdulalil A; Gibbs S; Skowronek AJ; Knostman K; Bailey J; Smith J; Vinci T; Wood B; Knopp MV; Roche BM
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):54-63. PubMed ID: 30195582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
    Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
    BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
    Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
    Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.
    Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H
    Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Gangasani JK; Challa VS; Vaidya JR; Kundu GC; Naidu VGM
    Chem Biol Interact; 2023 Aug; 381():110566. PubMed ID: 37257577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li D; Lu J; Guo C
    Toxicol Lett; 2016 Sep; 259():124-132. PubMed ID: 27491883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
    Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
    Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
    Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
    Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aidi injection reduces doxorubicin-induced cardiotoxicity by inhibiting carbonyl reductase 1 expression.
    Lu Y; Liu W; Lv T; Wang Y; Liu T; Chen Y; Jin Y; Huang J; Zheng L; Huang Y; He Y; Li Y
    Pharm Biol; 2022 Dec; 60(1):1616-1624. PubMed ID: 35980105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
    Licata S; Saponiero A; Mordente A; Minotti G
    Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative In Vitro Study of the Cytotoxic Effects of Doxorubicin's Main Metabolites on Cardiac AC16 Cells Versus the Parent Drug.
    Reis-Mendes A; Vitorino-Oliveira C; Ferreira M; Carvalho F; Remião F; Sousa E; de Lourdes Bastos M; Costa VM
    Cardiovasc Toxicol; 2024 Mar; 24(3):266-279. PubMed ID: 38347287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity.
    Zhu JN; Fu YH; Hu ZQ; Li WY; Tang CM; Fei HW; Yang H; Lin QX; Gou DM; Wu SL; Shan ZX
    Sci Rep; 2017 Sep; 7(1):11879. PubMed ID: 28928469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.